Isabel Kalofonos
CIK: 0001975163
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Oct 15, 2026CGON
CG Oncology, Inc.
Award(A)DirectEmployee Stock Option (right to buy)
92K shares- - Sep 1, 2026CRNX
Crinetics Pharmaceuticals, Inc.
Disposition(D)Direct1.7K shares at avg. $85.00$142K - Sep 1, 2026CRNX
Crinetics Pharmaceuticals, Inc.
Disposition(D)Direct34K shares at avg. $85.00$2.9M - Feb 23, 2026CRNX
Crinetics Pharmaceuticals, Inc.
Award(A)Direct34K shares- - Jan 5, 2026CRNX
Crinetics Pharmaceuticals, Inc.
Exercise(M)Direct2.5K shares at avg. $40.59$101K - Jan 5, 2026CRNX
Crinetics Pharmaceuticals, Inc.
Sale(S)Direct2.5K shares at avg. $55.00$138K - Jan 10, 2025CRNX
Crinetics Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
100K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 15, 2026 |  CGON CG Oncology, Inc. | Award(A) Employee Stock Option (right to buy) | 92,000 | - | - | Direct |
| Sep 1, 2026 |  CRNX Crinetics Pharmaceuticals, Inc. | Disposition(D) | 1,669 | $85.00 | $141,865 | Direct |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Disposition(D) | 34,000 | $85.00 | $2,890,000 | Direct |
| Feb 23, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Award(A) | 34,000 | - | $0 | Direct |
| Jan 5, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Exercise(M) | 2,500 | $40.59 | $101,475 | Direct |
| Jan 5, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Sale(S) | 2,500 | $55.00 | $137,500 | Direct |
| Jan 10, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 100,000 | - | - | Direct |
1-7 of 7 transactions
About Kalofonos Isabel
Kalofonos Isabel (SEC CIK 0001975163) files insider reports with the SEC as Chief Commercial Officer of CG Oncology, Inc. (CGON) and Chief Commercial Officer of Crinetics Pharmaceuticals, Inc. (CRNX).
Signal8 holds 7 ownership filings by Kalofonos Isabel (2 Form 3, 5 Form 4), filed between Dec 30, 2024 and Oct 19, 2026. Those filings report 7 transactions, from Jan 10, 2025 to Oct 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kalofonos Isabel's filings is in DALLAS, TX.
Recent filings by Kalofonos Isabel
- Oct 15, 2026: Grant or award of CGON derivative securities (Form 4, code A).
- Sep 1, 2026: Disposition to issuer transactions of CRNX shares (2 lines, Form 4, code D).
- Feb 23, 2026: Grant or award of CRNX shares (Form 4, code A).
- Jan 5, 2026: Option exercise of CRNX shares (Form 4, code M).
- Jan 5, 2026: Open-market sale of CRNX shares (Form 4, code S).
Other insiders filing for CG Oncology, Inc. (CGON)
- POST LEONARD E, Director
- Mulay James, Director
- Liu Brian Guan-Chyun, Director
- Tong Victor Edward Jr, Director
- Rossi Christina, Director
- Graf Susan E, Director